<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354987</url>
  </required_header>
  <id_info>
    <org_study_id>152BE18037</org_study_id>
    <nct_id>NCT04354987</nct_id>
  </id_info>
  <brief_title>Compare the Pharmacokinetics and Safety of CKD-391</brief_title>
  <official_title>Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D090 and D337 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      phase I clinical trial to compare the pharmacokinetics and safety of CKD-391 with
      co-administration of D090 and D337 in healthy adult volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0~72hours</time_frame>
    <description>To evaluate pharmacokinetic equivalence of experimental arm comparing Cmax
1) Atorvastatin, unconjugated ezetimibe(Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0~72hours</time_frame>
    <description>To evaluate pharmacokinetic equivalence of experimental arm comparing AUCt
1) Atorvastatin, unconjugated ezetimibe(AUCt)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R+R+T+T Period 1 : R Period 2 : R Period 3 : T Period 4 : T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R+T+R+T Period 1 : R Period 2 : T Period 3 : R Period 4 : T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T+R+T+R Period 1 : T Period 2 : R Period 3 : T Period 4 : R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T+T+R+R Period 1 : T Period 2 : T Period 3 : R Period 4 : R</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-391 10/10mg</intervention_name>
    <description>Drug T: CKD-391 10/10mg(Other Name: Test Drug)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Test Drug (T)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D090, D337</intervention_name>
    <description>D090 and D337 co-administration(Other Name: Reference drug)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Reference Drug (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 aged and 45 aged in healthy male adult

          2. Subjects in good health as determined by physical exams and medical examinations. No
             congenital or chronic diseases and no abnormal signs determined by medical
             examinations.

          3. Not abnormal or not clinically significant lab values.

          4. Subjects who signed informed consent form with good understandings after explanations
             by investigators.

        Exclusion Criteria:

          1. No history or presence of clinically significant diseases.

          2. Subjects showing adverse reaction to investigational product

          3. Genetic problems in galactose intolerance, Lapp lactose deficiency, or
             glucose-galactose malabsorption.

          4. History of myopathy

          5. unable to stop drinking and smoking during clinical trials

          6. Subjects who donated whole blood within 60 days or donated component blood within 30
             days or received blood transfusion within 30 days

          7. History of drug abuse

          8. Disagree to contraception

          9. Subjects who are in any conditions impossible participating in the clinical trials
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jae-Yong Chung</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Seongnam-si</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

